PCRX

Pacira is a single-segment specialty pharma built around three non-opioid pain assets — EXPAREL, ZILRETTA and iovera — with an emerging gene-therapy optionality in PCRX-201 from the February 2025 GQ Bio acquisition. The MD&A is explicit that management intends to keep spending: 'expand and enhance our manufacturing capacity,' 'invest in sales and marketing resources,' and 'progress our product candidate pipeline, including the development of PCRX-201.' That posture is showing up in the P&L — R&D jumped 43.8% to $117M in FY2025 — and it explains why, despite revenue growing for a fifth straight year to $726M, operating margin is just 2.6% and net margin 1.0%. The company's own performance graph quantifies the pain: a $100 investment in PCRX at end-2020 was worth $43.25 at end-2025, versus $180.33 for the Nasdaq Composite — a brutal five-year underperformance that frames why the stock screens 'cheap' at 1.3x sales.

The balance sheet still works, but it is being actively drained. Cash fell 42.7% to $159M while the company paid $148M to repurchase stock (a 493% jump YoY) and shares outstanding fell 12.5% to 40.5M — an unusually aggressive buyback for a company earning only $7M of GAAP net income. Long-term debt of $372M is manageable against $693M of equity (0.82x liabilities/equity) and operating cash flow of $152M, but current portion of debt going from materially positive to zero, combined with the cash burn into buybacks, means the financial cushion is thinner than the headline equity suggests. Retained earnings remain at -$199M, a reminder that cumulative GAAP profitability is still negative.